{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T05:10:50Z","timestamp":1794978650771,"version":"4.9.1"},"reference-count":40,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,24]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20\u00d7CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosunetuzumab for previously untreated follicular or marginal zone lymphoma in a phase 2 clinical trial. Analyses included flow cytometry, cytokine profiling, and RNA sequencing of isolated CD8+ T cells with T-cell receptor repertoire inference. Early (3 weeks) on-treatment samples showed broad cytokine induction, CD8+ T-cell redistribution with decreased CD45RA+ terminally differentiated effector cells and increased CD27+CD62L+ transitional effector memory\u2013like cells, increased PD-1 and LAG-3 expression, and induction of CD8+ transcriptional programs consistent with activation, proliferation, exhaustion priming, and SREBF2-regulated cholesterol metabolism. By midtreatment (3 months), activation-associated features contracted toward baseline, with no evidence of phenotypic exhaustion, although LAG3, HAVCR2, and LAYN remained persistently overexpressed on RNA sequencing, along with sustained SREBF2 activation. CD8+ T-cell clonality increased at midtreatment compared with baseline, and higher clonality was associated with early clinical complete response. Mosunetuzumab also induced indirect natural killer (NK)\u2013cell activation and expansion, including skewing toward CD56dimCD16bright effector state. HLA-DR upregulation on NK cells correlated with early increases in NK-activating plasma cytokines, and higher NK-cell count at midtreatment was associated with complete response. Together, these findings define a CD8+ effector-remodeling state during mosunetuzumab therapy, characterized by clonal expansion, selective inhibitory receptor expression, sustained activation of cholesterol biosynthesis, and cytokine-linked engagement of innate immune mechanisms, providing a framework for potential strategies to support T-cell function and enhance bispecific antibody efficacy. This trial was registered at www.clinicaltrials.gov as NCT04792502.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026021450","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T20:54:59Z","timestamp":1789073699000},"page":"7558-7570","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Peripheral CD8+ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2305-6299","authenticated-orcid":false,"given":"Charles J.","family":"Milrod","sequence":"first","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chorzalska","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7805-1209","authenticated-orcid":false,"given":"Dennis","family":"Bonal","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morgan","sequence":"additional","affiliation":[{"name":"2Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6777-2289","authenticated-orcid":false,"given":"Makayla","family":"Pardo","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas A.","family":"Ollila","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3354-4499","authenticated-orcid":false,"given":"Ari","family":"Pelcovits","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8715-3207","authenticated-orcid":false,"given":"Christina","family":"Raker","sequence":"additional","affiliation":[{"name":"2Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana O.","family":"Treaba","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"McMahon","sequence":"additional","affiliation":[{"name":"2Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Donnelly","sequence":"additional","affiliation":[{"name":"2Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7935-3620","authenticated-orcid":false,"given":"Caylee","family":"Carmody","sequence":"additional","affiliation":[{"name":"2Rhode Island Hospital, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5747-4939","authenticated-orcid":false,"given":"Jeannine","family":"Margolis","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4581-3721","authenticated-orcid":false,"given":"Matthew","family":"Matasar","sequence":"additional","affiliation":[{"name":"3Division of Blood Disorders, Rutgers University, New Brunswick, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7071-6475","authenticated-orcid":false,"given":"Scott","family":"Huntington","sequence":"additional","affiliation":[{"name":"4Department of Internal Medicine, Yale University, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-0647","authenticated-orcid":false,"given":"Patrycja M.","family":"Dubielecka","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6472-6658","authenticated-orcid":false,"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"1Department of Medicine, Brown University, Providence, RI"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2026111214370239300_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"17","key":"2026111214370239300_bib2","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1182\/bloodadvances.2021004535","article-title":"The rules of T-cell engagement: current state of CAR T cells and bispecific antibodies in B-cell lymphomas","volume":"8","author":"Haydu","year":"2024","journal-title":"Blood Adv"},{"issue":"7","key":"2026111214370239300_bib3","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1182\/blood.2024025454","article-title":"Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after \u22652 prior therapies","volume":"145","author":"Sehn","year":"2025","journal-title":"Blood"},{"issue":"9","key":"2026111214370239300_bib4","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood.2023022348","article-title":"Loss of CD20 expression as a mechanism of resistance to mosunetuzumab in relapsed\/refractory B-cell lymphomas","volume":"143","author":"Schuster","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026111214370239300_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen-loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"8","key":"2026111214370239300_bib6","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2026111214370239300_bib7","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"15","key":"2026111214370239300_bib8","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1182\/blood.2025028863","article-title":"Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma","volume":"146","author":"Sam","year":"2025","journal-title":"Blood"},{"issue":"suppl 7","key":"2026111214370239300_bib9","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1538-7445.AM2023-3248","article-title":"Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma [abstract]","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res"},{"issue":"suppl 1","key":"2026111214370239300_bib10","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/blood-2025-3566","article-title":"Exposure to epcoritamab is associated with improved T-cell functionality and dynamic changes in CD8+ T-cells in diffuse large B-cell lymphoma: insights from epcore NHL-6","volume":"146","author":"Takacs","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026111214370239300_bib11","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1158\/2326-6066.CIR-23-0072","article-title":"T cell-dependent bispecific therapy enhances innate immune activation and antibody-mediated killing","volume":"12","author":"Besla","year":"2024","journal-title":"Cancer Immunol Res"},{"issue":"suppl 1","key":"2026111214370239300_bib12","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1182\/blood-2025-1003","article-title":"Mosunetuzumab with response-driven lenalidomide augmentation achieves high response rates and immune reprogramming in untreated follicular and marginal zone lymphoma: a multicenter phase 2 trial","volume":"146","author":"Olszewski","year":"2025","journal-title":"Blood"},{"key":"2026111214370239300_bib13","volume-title":"LUNSUMIO VELO\u2122 (mosunetuzumab-axgb). Prescribing information","year":"2025"},{"issue":"27","key":"2026111214370239300_bib14","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026111214370239300_bib15","doi-asserted-by":"crossref","first-page":"113379","DOI":"10.1016\/j.jim.2022.113379","article-title":"Comparative flow cytometry-based immunophenotyping analysis of peripheral blood leukocytes before and after fixation with paraformaldehyde","volume":"511","author":"Vistica Sampino","year":"2022","journal-title":"J Immunol Methods"},{"issue":"7","key":"2026111214370239300_bib16","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"2026111214370239300_bib17","doi-asserted-by":"crossref","first-page":"748","DOI":"10.12688\/f1000research.11622.1","article-title":"CyTOF workflow: differential discovery in high-throughput high-dimensional cytometry datasets","volume":"6","author":"Nowicka","year":"2017","journal-title":"F1000Res"},{"issue":"4","key":"2026111214370239300_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-025-01238-2","article-title":"Guidelines for T cell nomenclature","volume":"26","author":"Masopust","year":"2026","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"2026111214370239300_bib19","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41592-024-02530-0","article-title":"Integrative mapping of human CD8+ T cells in inflammation and cancer","volume":"22","author":"Xue","year":"2025","journal-title":"Nat Methods"},{"issue":"7","key":"2026111214370239300_bib20","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"issue":"13","key":"2026111214370239300_bib21","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"6","key":"2026111214370239300_bib22","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/s41592-021-01142-2","article-title":"TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data","volume":"18","author":"Song","year":"2021","journal-title":"Nat Methods"},{"issue":"6","key":"2026111214370239300_bib23","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1158\/1078-0432.CCR-22-2469","article-title":"T-cell receptor repertoire sequencing in the era of cancer immunotherapy","volume":"29","author":"Frank","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2026111214370239300_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.copbio.2020.07.010","article-title":"T-cell repertoire analysis and metrics of diversity and clonality","volume":"65","author":"Chiffelle","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"2026111214370239300_bib25","doi-asserted-by":"crossref","first-page":"378","DOI":"10.32614\/RJ-2017-066","article-title":"glmmTMB balances speed and flexibility among packages for zero-inflated generalized linear mixed modeling","volume":"9","author":"Brooks","year":"2017","journal-title":"R J"},{"issue":"9","key":"2026111214370239300_bib26","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41592-025-02793-1","article-title":"Reproducible single-cell annotation of programs underlying T cell subsets, activation states and functions","volume":"22","author":"Kotliar","year":"2025","journal-title":"Nat Methods"},{"issue":"9","key":"2026111214370239300_bib27","doi-asserted-by":"crossref","first-page":"e20192080","DOI":"10.1084\/jem.20192080","article-title":"Layilin augments integrin activation to promote antitumor immunity","volume":"217","author":"Mahuron","year":"2020","journal-title":"J Exp Med"},{"issue":"5","key":"2026111214370239300_bib28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"2026111214370239300_bib29","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1182\/blood-2019-123933","article-title":"Pharmacodynamic effects and immune correlates of response to the CD20\/CD3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma","volume":"134","author":"Hernandez","year":"2019","journal-title":"Blood"},{"issue":"10306","key":"2026111214370239300_bib30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"2026111214370239300_bib31","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"2026111214370239300_bib32","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab monotherapy in R\/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"2026111214370239300_bib33","doi-asserted-by":"crossref","first-page":"1285798","DOI":"10.3389\/fimmu.2024.1285798","article-title":"Cytotoxic CD8+ Temra cells show loss of chromatin accessibility at genes associated with T cell activation","volume":"15","author":"Turk","year":"2024","journal-title":"Front Immunol"},{"issue":"23","key":"2026111214370239300_bib34","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1182\/blood.2025031309","article-title":"Patient-derived lymphoma spheroids reveal predictive markers of glofitamab resistance in relapsed\/refractory B-NHL","volume":"147","author":"Marcoux","year":"2026","journal-title":"Blood"},{"issue":"5","key":"2026111214370239300_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/ni.2570","article-title":"Sterol regulatory element-binding proteins are essential for the metabolic programming of effector T cells and adaptive immunity","volume":"14","author":"Kidani","year":"2013","journal-title":"Nat Immunol"},{"issue":"7977","key":"2026111214370239300_bib36","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41586-023-06483-w","article-title":"Metabolic programs of T cell tissue residency empower tumour immunity","volume":"621","author":"Reina-Campos","year":"2023","journal-title":"Nature"},{"issue":"4","key":"2026111214370239300_bib37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"9","key":"2026111214370239300_bib38","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1038\/s41591-020-1006-1","article-title":"A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma","volume":"26","author":"Cader","year":"2020","journal-title":"Nat Med"},{"key":"2026111214370239300_bib39","doi-asserted-by":"crossref","first-page":"807696","DOI":"10.3389\/fimmu.2022.807696","article-title":"Revealing clonal responses of tumor-reactive T-cells through T cell receptor repertoire analysis","volume":"13","author":"Aoki","year":"2022","journal-title":"Front Immunol"},{"issue":"10524","key":"2026111214370239300_bib40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0140-6736(25)02360-8","article-title":"Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial","volume":"407","author":"Falchi","year":"2026","journal-title":"Lancet"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7558\/2600140\/blooda_adv-2026-021450-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/22\/7558\/2600140\/blooda_adv-2026-021450-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T19:37:11Z","timestamp":1794512231000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/22\/7558\/570890\/Peripheral-CD8-T-cell-clonality-and-NK-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11,24]]},"references-count":40,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,11,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026021450","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11,24]]},"published":{"date-parts":[[2026,11,24]]}}}